key: cord-1048236-59up4v56
authors: Ceban, Felicia; Ling, Susan; Lui, Leanna M.W.; Lee, Yena; Gill, Hartej; Teopiz, Kayla M.; Rodrigues, Nelson B.; Subramaniapillai, Mehala; Di Vincenzo, Joshua D.; Cao, Bing; Lin, Kangguang; Mansur, Rodrigo B.; Ho, Roger C.; Rosenblat, Joshua D.; Miskowiak, Kamilla W.; Vinberg, Maj; Maletic, Vladimir; McIntyre, Roger S.
title: Fatigue and Cognitive Impairment in Post-COVID-19 Syndrome: A Systematic Review and Meta-Analysis
date: 2021-12-29
journal: Brain Behav Immun
DOI: 10.1016/j.bbi.2021.12.020
sha: 9408f81b594bc8956fdff094312f75cea02d5db4
doc_id: 1048236
cord_uid: 59up4v56

Importance COVID-19 is associated with clinically significant symptoms despite resolution of the acute infection (i.e., post-COVID-19 syndrome). Fatigue and cognitive impairment are amongst the most common and debilitating symptoms of post-COVID-19 syndrome. OBJECTIVE: To quantify the proportion of individuals experiencing fatigue and cognitive impairment 12 or more weeks following COVID-19 diagnosis, and to characterize the inflammatory correlates and functional consequences of post-COVID-19 syndrome. DATA SOURCES: Systematic searches were conducted without language restrictions from database inception to June 8, 2021 on PubMed/MEDLINE, The Cochrane Library, PsycInfo, Embase, Web of Science, Google/Google Scholar, and select reference lists. STUDY SELECTION: Primary research articles which evaluated individuals at least 12 weeks after confirmed COVID-19 diagnosis and specifically reported on fatigue, cognitive impairment, inflammatory parameters, and/or functional outcomes were selected. DATA EXTRACTION & SYNTHESIS: Two reviewers independently extracted published summary data and assessed methodological quality and risk of bias. A meta-analysis of proportions was conducted to pool Freeman-Turkey double arcsine transformed proportions using the random-effects restricted maximum-likelihood model. MAIN OUTCOMES & MEASURES: The co-primary outcomes were the proportions of individuals reporting fatigue and cognitive impairment, respectively, 12 or more weeks after COVID-19 infection. The secondary outcomes were inflammatory correlates and functional consequences of post-COVID-19 syndrome. RESULTS: The literature search yielded 10,979 studies, and 81 studies were selected for inclusion. The fatigue meta-analysis comprised 68 studies, the cognitive impairment meta-analysis comprised 43 studies, and 48 studies were included in the narrative synthesis. Meta-analysis revealed that the proportion of individuals experiencing fatigue 12 or more weeks following COVID-19 diagnosis was 0.32 (95% CI, 0.27, 0.37; p < 0.001; n = 25,268; I(2)=99.1%). The proportion of individuals exhibiting cognitive impairment was 0.22 (95% CI, 0.17, 0.28; p < 0.001; n = 13,232; I(2)=98.0). Moreover, narrative synthesis revealed elevations in proinflammatory markers and considerable functional impairment in a subset of individuals. CONCLUSIONS & RELEVANCE: A significant proportion of individuals experience persistent fatigue and/or cognitive impairment following resolution of acute COVID-19. The frequency and debilitating nature of the foregoing symptoms provides the impetus to characterize the underlying neurobiological substrates and how to best treat these phenomena. Study Registration PROSPERO (CRD42021256965)

The global confirmed case count of coronavirus disease 2019 (COVID- 19) surpassed 265 million as of December 2021. 1 The actual case positive rate, however, is estimated to be much higher with multiple models predicting the actual number to be 10 (3 to 24) times greater than the number of confirmed cases. [2] [3] [4] In keeping with this view, a projection of over 2.65 billion people may have been infected by More than 30% of individuals affected by COVID-19, 5 including asymptomatic cases, 6 and approximately 80% of patients hospitalized for COVID-19 7 experience post-COVID sequelae. Fatigue and cognitive impairment, along with other enduring neuropsychiatric (e.g., depression) 8 and physical (e.g., dyspnea) manifestations, comprise 'post-acute sequelae of SARS-CoV-2' (i.e., symptoms persisting for at least 4 weeks following infection), 9 colloquially referred to as 'long COVID'. 10 The National Institute for Health and Care Excellence (NICE) defines 'post-COVID-19 syndrome' (PCS) as a constellation of symptoms which develop during or following COVID-19 infection, persist for more than 12 weeks, and are not sufficiently explained by alternative diagnoses. 11 Towards the aim of identifying a common nomenclature in case definition, the World Health Organization (WHO) has recently proposed the moniker 'post COVID-19 condition'. 12 Post COVID-19 condition is defined as persistent symptoms usually occurring 3 months from the onset in individuals with past confirmed or probable SARS-CoV-2 infection and persisting for at least 2 months which cannot be explained by an alternative diagnosis. 12 Research efforts into PCS were originated by online patient advocacy groups, who have reported substantial detriments to quality of life and daily functioning as a consequence of persistent symptoms, lack of formal diagnosis, and effective established treatments. 13, 14 Fatigue and cognitive impairment have been consistently reported to be some of the most common and debilitating features of PCS. [15] [16] [17] Chronic fatigue 18 and cognitive impairment 19, 20 constitute a significant global economic burden, respectively. Unlike other common symptoms of PCS including dyspnea and depression, there are no established and effective treatments for post-viral fatigue and cognitive impairment, as well as related conditions such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The global incidence of infection and the potential economic burden and quality of life diminution provide the impetus for identifying neurobiological substrates subserving PCS-related fatigue and cognitive impairment, associated factors and determinants, as well as safe and effective treatments. Herein, we sought to determine the proportion of individuals exhibiting fatigue and cognitive impairment 12 or more weeks following COVID-19 diagnosis, including amongst age, sex, and clinical subgroups. We additionally aimed to characterize the inflammatory correlates and functional consequences of PCS.

The protocol pertaining to this systematic review and meta-analysis was registered on PROSPERO (CRD42021256965). This study followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines. 21 In accordance with the 2020 Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, 22 a systematic search was conducted on PubMed/MEDLINE, Cochrane Library, PsycInfo, EMBASE, and Web of Science from database inception to June 8, 2021 . The search string implemented was: "long covid" OR "persistent covid" OR "post covid" OR "post-acute sequelae of SARS-CoV-2 PASC"

OR "enduring COVID-19 sequelae" OR "long-haul covid" OR "long-tail covid". We manually searched the references of relevant articles, as well as Google Scholar/Google, for additional studies. No language or publication date restrictions were imposed.

Titles and abstracts were independently screened by two review authors (FC and SL) using the Covidence platform. 23 Articles identified as potentially relevant by at least one reviewer were retrieved, and duplicates were removed. Full text-articles were independently screened by two reviewers (FC and SL), with discrepancies resolved through discussion. Authors of potentially eligible studies were contacted to provide clarification and/or supplementary data where necessary.

We sought articles reporting on the incidence of any primary outcome (i.e., fatigue, cognitive impairment) and/or secondary outcome (i.e., inflammatory markers, functional outcomes/quality of life), as defined in Table 1 , in individuals with confirmed COVID-19 12 or more weeks following initial diagnosis. At the outset, we planned to determine the secondary outcomes solely for fatigue and cognitive impairment in PCS. However, due to the paucity of data concerning the foregoing, we subsequently included inflammatory correlates and functional outcomes pertaining to any PCS symptoms. Inclusion criteria were established prior to article review and were as follows:

1.

Complete summary estimates (i.e., exact proportions) pertaining to at least one primary outcome, and/or qualitative or quantitative data pertaining to at least one secondary outcome, as defined in Table 1 , for individuals previously diagnosed with COVID-19 of any age, sex, or ethnicity.

Median or mean follow-up time of at least 12 weeks (84 days) since COVID-19 diagnosis, to serve as a proxy for time since infection, in accordance with the 8. Case series, or any study design wherein participants are selected for inclusion based on the presence of post-COVID-19 syndrome symptoms (outcomes).

Unpublished study, abstract, case report, study with a sample size of less than 10, or protocol.

Non-primary research.

Published summary data from included articles were independently extracted by two reviewers (FC and SL) using a piloted data extraction form, then corroborated, with discrepancies resolved through discussion. Information to be extracted was established a priori and included study characteristics, participant characteristics and subgroups, sample size and source, modes of ascertainment, follow-up period, exact proportions (including subgroup-specific data) pertaining to primary or secondary outcomes, qualitative data pertaining to secondary outcomes, and factors reportedly associated with PCS.

Methodological quality and risk of bias was assessed using the Newcastle-Ottawa Scale (NOS), 24 modified for applicable cohort and case-control studies, as well as adapted for crosssectional studies. Studies wherein design was unclear were assessed according to the prospective cohort NOS. Cohort studies were penalized for failing to include a non-exposed cohort. All component studies were independently rated by two reviewers (FC and LMWL) and results were corroborated, with discrepancies resolved through discussion. Modified NOSs and methodological quality rankings for each study type are provided (supplementary material).

A meta-analysis of proportions was conducted using R version 4.1.0 (R Foundation for Statistical Computing). An α level of 0.05 was chosen to indicate statistical significance. In anticipation of marked heterogeneity, the meta::metaprop function 25 was used to pool proportions, indicated as the number of cases exhibiting fatigue or cognitive impairment (events) divided by the size of the sample (observations), via the random-effects restricted maximumlikelihood model (REML). 26, 27 Where one study reported multiple proportions qualifying as a primary outcome measure (e.g., concentration impairment and memory impairment, which can both be subsumed under cognitive impairment), only the largest proportion was included to prevent data duplication or skewing of true effect size. Where studies provided data for multiple qualifying follow-up periods, the earliest follow-up was used in the main analyses. Single proportions were transformed via the Freeman-Tukey Double arcsine method to stabilize variances, 27 Clopper-Pearson 95% confidence intervals (CIs) were calculated for individual studies, and Wald 95% CIs were calculated for pooled proportions. Forest plots for each primary outcome were created via the meta::forest function. Random effects subgroup analyses, established a priori, for sex, COVID-19 hospitalization status, age group (children vs adults, defined as median/mean age <18 and ≥18 years, respectively), follow-up duration (<6 months vs ≥6 months), and mode of ascertainment (objective vs subjective) were conducted using the byvar argument, assuming separate estimates of between-study variance for each subgroup. Study populations were classified as comprising hospitalized populations if ≥80% of the participants had been hospitalized for COVID-19 (and vice versa for outpatients). Post hoc sensitivity analyses according to NOS quality rating as well as by study design were undertaken. Statistically significant differences in inter-group effect sizes were calculated via the Wald-type χ2 test. Heterogeneity was quantified using the I 2 statistic, where the cut-offs 30.0%, 50.0%, and 75.0% denote moderate, substantial, and considerable heterogeneity, respectively, as recommended by GRADE (Grading of Recommendations, Assessment, Development and

Evaluations) criteria and the Cochrane Handbook's interpretation of heterogeneity scores. 28, 29 The

Egger regression intercept test and the Begg and Mazumdar rank correlation test, as well as visual inspection of funnel plots for asymmetry, were used to assess publication bias via the meta::metabias and meta::funnel functions, respectively. Qualitative analysis via narrative synthesis was performed for secondary outcomes, which were not sufficiently homogenous to meta-analyze.

The literature search yielded 10,979 studies. Following the removal of duplicates, 5965 studies were screened by title and abstract, producing 229 eligible studies. 148 studies were further excluded following full-text screening. Details of study selection are provided in Figure 1 .

In total, 81 studies were included in the review: 56 prospective cohort studies, 14 Ten studies analyzed data from Italy, nine from Spain, eight from the US, seven from   China, six from the UK, three from Denmark, France, and Norway, respectively, two from Australia, Austria, Brazil, Canada, Egypt, Germany, Israel, Russia, and the Netherlands, respectively, and one from Belgium, the Czech Republic, England, Faroe Islands, Iran, Japan, Mexico, Pakistan, Singapore, Sweden, Switzerland, and Turkey, respectively. Sample sizes ranged from 23 to 2649, and median or mean follow-up periods ranged from 2.8 to 11.2 months.

Six study authors provided confirmation regarding mode of ascertainment of COVID-19, 37-42 and one author 43, 44 confirmed that there was no sample duplication among two component studies, as well as advised the exclusion of a third study on the basis of possible duplication. Table 2 provides detailed characteristics and summaries of applicable findings for all 81 component studies.

Taken together, the NOS rating of the component studies was moderate, evidenced by mean scores of 6.0 out of 9 for prospective/ambidirectional cohort studies, 4.0 out of 6 for retrospective cohort studies, and 5.6 out of 9 for cross-sectional studies. Common methodological limitations were the failure to include a non-exposed group in cohort studies, failure to ascertain whether outcomes were present prior to COVID-19 infection, and a lack of sample size justification in cross-sectional studies. NOS scores within each category for all component studies organised by design are included (Table S1 in the supplementary material).

We conducted sensitivity analyses a posteriori to compare pooled proportions across high, moderate, and low NOS-ranked studies. Studies of moderate NOS rank reported higher proportions of individuals exhibiting cognitive impairment when compared to low and high NOS-13 ranked studies (p = 0.035; Table 3 ). However, the proportion of individuals experiencing fatigue did not significantly differ across NOS ranking categories (p = 0.885; Table 3 ).

Meta-analyses of the two primary outcomes indicated that 32% of individuals experienced fatigue and 22% of individuals exhibited cognitive impairment 12 or more weeks following COVID-19 diagnosis. Furthermore, 13 of 14 studies examining inflammatory parameters reported elevations in proinflammatory markers (i.e., proinflammatory cytokines, C-reactive peptide, Ddimer, and procalcitonin) in a subset of patients. All studies investigating functional outcomes reported marked functional impairment in a sample subset.

The pooled proportion of individuals experiencing fatigue amongst COVID-19 patients 12 or more weeks following diagnosis was 0.32 (95% CI, 0.27, 0.37; p < 0.001; n = 25,268; Figure   2 ). A larger proportion of females reported fatigue as compared to males, but the inter-subgroup difference was not statistically significant (0.46 of females vs. 0.30 of males; p subgroup = 0.067; Table 3 ). Sensitivity analyses revealed that stratifying studies by design produced statistically significant differences in effect size, although the effect sizes between prospective cohort, retrospective cohort, cross-sectional studies (i.e., the 3 most common study designs) did not significantly differ.

The pooled proportion of individuals exhibiting cognitive impairment amongst COVID-19 patients 12 or more weeks following diagnosis was 0.22 (95% CI, 0.17, 0.28; p < 0.001; n = 13,232; Figure 3 ). There was a non-significant trend towards a greater proportion of females than males who exhibited cognitive impairment, (0.56 of females vs. 0.36 of males; p subgroup = 0.063; Table 3 ), however, the subgroup proportion for females was not statistically significant (0.56; 95% CI, 0.46, 0.66; p = 0.960; Table 3 ). There was a significant trend towards a greater proportion of adults than children exhibiting cognitive impairment (0.23 of adults vs. 0.09 of children; p subgroup < 0.001; Table 3 ), however, the pooled subgroup proportion of children experiencing cognitive impairment was not significant (0.09; 95% CI, 0.08, 0.10; p = 0.400; Table 3 ). Unlike for fatigue, stratifying studies by design did not produce any statistically significant differences in effect sizes (p subgroup = 0.366; Table 3 ).

The fatigue (I 2 =99.1%) and cognitive impairment (I 2 =98.0%) meta-analyses exhibited considerable heterogeneity. Select subgroup analyses resulted in a reduction in heterogeneity (Table 3) .

Visual inspection of funnel plot asymmetry for the fatigue meta-analysis did not suggest the presence of publication bias (Supplementary, Figure S1 ), and neither the Egger regression intercept test (intercept = 0.538; SE = 0.061; p = 0.390) nor the Begg and Mazumdar rank correlation test (p = 0.857) were statistically significant. Conversely, visual inspection of funnel plot asymmetry for the cognitive impairment meta-analysis suggested the presence of publication bias (Supplementary, Figure S2 ); the Egger regression intercept test was statistically significant (intercept = 0.187; SE = 0.040; p < 0.001), whereas the Begg and Mazumdar rank correlation test was not significant (p = 0.818).

14 studies investigated peripheral inflammatory parameters in COVID-19 patients 12 or more weeks following diagnosis. [30] [31] [32] 36, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] Of those which quantified intracellular cytokine levels, Breton et al. reported marked increases in the numbers of CD4+ T cells expressing the inflammatory cytokines interleukin (IL)-2, interferon (IFN)-γ, and tumor necrosis factor (TNF)-α in individuals with prior COVID-19 as compared with healthy donors. 30 Ong et al., reported that previously-hospitalized patients exhibited elevated levels of proinflammatory cytokines, including but not limited to macrophage inflammatory protein 1β, IL-1β, and IL-17A. 48 Ong et al. additionally reported that concentrations of the proinflammatory factors IL-1β, IL-17A, IL-12p70, stem cell factor (SCF), and MIP-1β were significantly higher in prior COVID-19 patients compared to healthy controls, regardless of acute phase severity. 48 Moreover, Shuwa et al. determined that patients with prior moderate to severe illness demonstrated an elevation in most cytokine-producing T cells as well as increased production of cytokines, whereas no significant differences in the frequency of TNF-α+ B cells were observed. 31 and IL-10 across all groups. 36 Between 1.8% to 24.5% of patients exhibited elevated CRP levels, 32, 45, 49, 50, 52 operationalized as >10 mg/L or >2.9 mg/dL. Median CRP levels ranged between 0.6 -2.9 mg/L. 36, 47, 51, 53 Moreover, 9.8% to 38.0% of patients exhibited elevated levels of D-dimer (≥ 500 ng/mL). 32, 46, 49, 50, 52, 54 Conversely, Zhou et al. reported that CRP and D-dimer levels were not significantly elevated compared to healthy controls (p>0.05), but that cytokines such as TNF-α were correlated with abnormal clinical features. 36 In addition, Sonnweber et al. reported elevated procalcitonin levels in 9.0% of patients (mean 0.07). 32 Taken together, 13 of 14 studies (all except van den Borst et al.) 53 examining inflammatory parameters report elevation in at least one measure of inflammation in a subset of patients or across the whole post-COVID sample (as a median/mean, compared to healthy controls or standard reference values). It should be noted that nine of 14 studies reported both the presence of proinflammatory markers as well as persistent fatigue and/or cognitive impairment within their sample, [45] [46] [47] [48] [49] [50] [51] [52] 54 and several studies noted an association between elevation in measures of inflammation and PCS symptoms. 49 33, 42, 49, 53, 59, 60, 68, 69, [71] [72] [73] and three via self-report, 37, 44, 63 with some studies implementing multiple assessment tools. All studies demonstrated functional impairment or reduction in at least one QOL dimension (in up to 72% of patients) 53 compared to regional norms, uninfected controls, or pre-COVID status, and four studies reported decrements across all QOL dimensions. 42, 45, 53, 66 Functional impairment post-COVID was exhibited by 21% to 63% of individuals; 33, 72, 76 activity impairment (including difficulties with performing daily tasks, self-care, and mobility) in 1.0% to 68.4% 7, 34, 57, [59] [60] [61] 64, 65, 67, [74] [75] [76] , social impairment in 5% to 15% 56, 59, 62, 77 , and 16.0% to 28.2% reportedly unable to partake in a sport/recreational activity. 44, 58, 69 One in five previously hospitalized persons reached the threshold for an additional disability on the Washington Group Short Set on Functioning (WG-SS) scale. 49 Moreover, between 29.0% to 47.4% of those who were employed premorbidly were not able to return to work, 37, 57, 58, 60, 62 5% to 90% were unable to reach their pre-COVID employment level, 49, 62, 77 and between 8.0% to 38.9% reported disruption in work life. 59, 60, 65, 74 Comprehensive results, including mean and median scores on QOL scales where reported, are available in Table 2 . EQ-5D population norms are provided elsewhere. 78 

Overall, 53 of out 81 studies reported factors associated with increased incidence of PCS symptoms according to their respective analyses. Female sex was associated with an increased risk of developing PCS symptoms (including fatigue and cognitive impairment, in some cases), a 32, 34, 43, 49, 64, 68, 79, 89, 95 Furthermore, greater severity of acute disease, hospitalization, or increased length of hospital stay were associated with PCS symptoms or QOL decrements in 19 studies. 7, [32] [33] [34] 39, 43, 45, 48, 49, 56, 60, 64, 76, 82, 83, 85, 86, 91, 96 Interestingly, Jacobson et al. reported that the presence of fatigue was associated with long-term activity impairment, 60 Miskowiak et al. reported that greater global cognitive impairment and executive dysfunction both correlated with greater difficulty within the EQ-5D 'usual activity' and 'anxiety and depression' domains, 65 and Soldati et al. reported that patients with mild cognitive impairment tended to have a low QOL score. 73 Moreover, Woo et al. reported that persistent neurocognitive deficits were independent from fatigue and mood alterations, and may thus differ from the classical post-viral syndrome. 97 Table 2 details all factors reportedly associated with PCS symptoms.

Herein we identified that approximately a third of individuals experienced persistent fatigue and over a fifth of individuals exhibited cognitive impairment 12 or more weeks following confirmed COVID-19 diagnosis. Similar incidences of fatigue and cognitive impairment, respectively, were observed amongst hospitalized and non-hospitalized populations. Furthermore, in contradistinction to other persistent symptoms which are self-limiting (e.g., anosmia) 98 , fatigue and cognitive impairment appear to endure and may potentially worsen over time in susceptible individuals, 99 as evidenced by similar proportions of affected individuals at <6 and ≥6 months follow-up. A lower incidence of fatigue and cognitive impairment, respectively, were identified amongst children as compared to adults. Moreover, we established that persistent inflammation was consistently reported in a subset of patients, and that symptoms of PCS (including fatigue and cognitive impairment) are associated with marked functional impairment. Frequently reported factors associated with a greater incidence of PCS symptoms amongst component studies included female sex, older age, greater severity of acute illness, and pre-existing comorbidities. In our meta-analysis, we similarly determined a non-significant trend towards a greater proportion of females than males exhibiting fatigue.

Fatigue and cognitive impairment in PCS comprise a form of postinfectious fatigue syndrome, and exhibit phenotypic similarity to ME/CFS, which is often precipitated by an infectious agent. 76 Similar incidence rates of fatigue, as well as decreased QOL measures, have been reported in the aftermath of previous coronavirus epidemics, including severe acute respiratory syndrome coronavirus (SARS) and Middle East respiratory syndrome coronavirus (MERS). 100, 101 Furthermore, PCS shares overlapping symptoms with the encephalitis lethargica epidemic (von Economo's encephalitis) of the 1920s (e.g., fatigue, cognitive impairment, headache), which was hypothesized to be causally related to the 1918 Spanish influenza pandemic. 102 There are multiple mechanisms whereby SARS-CoV-2 infection can engender or exacerbate persistent fatigue and/or cognitive impairment. Neurological dysfunction can ensue due to non-mutually exclusive factors including but not limited to direct viral encephalitis, neuroinflammation (including damage to blood-brain barrier integrity), 9,100,101 hypoxia, and cerebrovascular disease. 9, 103, 104 Multiple studies have identified neuroanatomical alterations and neurodegeneration, 105 cerebral microvascular injury, 106 and metabolic aberrations (including hypometabolism in areas associated with motivation, such as the dorsolateral prefrontal cortex) 107 in the brains of COVID-19 patients.

It is also recognized that systemic sequelae including endothelial dysfunction, 108 hyperinflammation, autoimmunity, latent viral reactivation, 109 multi-organ pathology, and autonomic nervous system dysfunction can interact with the foregoing in a synergistic manner. 110 The causal relationship between specific pro-inflammatory cytokines, mood symptoms, and cognitive decline is firmly established. 111, 112 We report that a subset of individuals consistently exhibited markers of inflammation following the resolution of acute COVID-19 infection, suggesting hyperinflammation is an amenable cause of fatigue and/or cognitive impairment in PCS. Indeed, other post-infectious syndromes (e.g., post-infectious encephalitis) 113 have been previously associated with elevations in inflammatory parameters. Several non-mutually exclusive hypotheses regarding the pathogenesis of PCS would suggest that anti-inflammatory pharmacologic approaches may be of some utility in select patients. Moreover, psychotropic medications (e.g., selective serotonin reuptake inhibitors) 114 may modulate pro-inflammatory cytokine levels, and possibly exert salutary effects on mood and cognition in COVID-19 survivors. 115 In addition to pharmacologic strategies, disparate psychosocial treatments (e.g., cognitive remediation) may also be effective in treating symptoms of PCS. There is also the need to determine whether the type and frequency of vaccines (i.e., boosters) influence the risk for incident, persistent and/or severity of PCS. Reports of breakthrough infections in persons previously receiving a full vaccination schedule invites the need for characterization of risk in that subset of individuals. Moreover, the influence of both medical and psychiatric comorbidity on the risk for PCS, notably cognitive impairment, as well as the moderating influence of social, economic, and spatial determinants of health should be evaluated.

The results presented herein should be interpreted within the context of several limitations.

First, component studies were observational, therefore causal relationships cannot be inferred.

Second, the majority of studies did not ascertain whether outcomes were present prior to COVID-19 infection (i.e., period prevalence rather than incidence), which is a limitation accounted for by the NOS. Thus, we cannot exclude the possibility that fatigue and cognitive impairment preceded SARS-CoV-2 infection (although infection may have exacerbated symptoms). Third, as most component studies were based on hospitalized individuals, the results may not be representative for the majority of individuals affected by COVID-19. Furthermore, it is firmly established that the incidence of depressive and anxious symptoms in the general population has increased since the pandemic onset; 116 fatigue and cognitive impairment may be consequences of chronic stress and/or depression resulting from social and economic challenges of COVID-19, rather than a result of infection, in a proportion of PCS patients. It is also noteworthy that social consequences may be exacerbated for infected individuals. The majority of cohort studies failed to include a non-exposed control group, providing no basis for comparison (see Table S1 in supplementary material).

With respect to selection bias, there is an overrepresentation of hospitalized cases in the analyses herein, and a subset of reports may be attributable to post-intensive care syndrome, comorbid conditions, and/or medications. 115 Conversely, PCS patients not receiving healthcare for their symptoms are underrepresented. Moreover, fatigue and cognitive impairment may be secondary to other sequelae of SARS-CoV-2 infection, including but not limited to major depressive disorder. 117 Another limitation in most studies of objective cognitive functions was the use of dementia screening tools (e.g., MoCA, TICS) that have limited sensitivity to cognitive decline in younger populations and may thus have led to underestimation of cognitive impairments. 118 Future studies would thus be recommended to apply more sensitive tools devoid of ceiling effects, for example the Screen for Cognitive Impairment for Psychiatry (SCIP) 65, 119 and THINC-integrated tool (THINC-it). [120] [121] [122] Another methodological limitation is the considerable level of heterogeneity exhibited in both meta-analyses, which may be attributable to variation in methods of data collection and sample characteristics amongst component studies. For example, the various subjective and objective assessment tools utilized differential scales (e.g., dichotomous Yes/No vs. Likert), providing varying levels of granularity. Stratifying studies by design, mode of ascertainment, and quality did not markedly reduce heterogeneity (Table 3) . We also included preprints (Table 2) , which have not undergone peer review.

In this systematic review and meta-analysis of 81 studies, we established that approximatelt a third of the included individuals experienced persistent fatigue and over a fifth of individuals exhibited cognitive impairment 12 or more weeks following COVID-19 diagnosis. 

RSM and FC conceptualized and designed study. FC and SL conducted literature search, study selection, and data extraction. FC and LMWL conducted quality and bias assessment of component studies. FC and YL conducted statistical analyses. FC interpreted statistical results, conducted qualitative analysis, and wrote the first draft of the manuscript with input from RSM, KWM, and MV. All authors provided critical review for important intellectual content, and approved the final version of the manuscript.

This research did not receive any grants or funding.

Institutes of Health Research (CIHR)/National Natural Science Foundation of China's Mental Health Team Grant; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. JDR is the medical director of Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. YL has received personal fees from Braxia Scientific Corp. LMWL is a contractor to Braxia Scientific Corp. KWM has received personal fees from Lundbeck and Janssen Cilag in the past three years and is supported by a five-year Lundbeck Foundation Fellowship (grant no. R215-2015-4121). MV has received a consultancy fee from Lundbeck, Janssen-Cilag and Sunovion. VM has received speaking/consulting and fees from: AbbVie/Allergan, Acadia Pharmaceuticals, Inc., Alfasigma, USA, Inc., Alkermes, Inc., Eisai-Purdue, Intra-Cellular Therapies, Ironshore. Janssen, Lundbeck A/S, Jazz Pharmaceuticals, Noven Pharmaceuticals Inc, Otsuka America Pharmaceutical, Inc., Sage Pharmaceuticals, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited KMT has received personal fees from Braxia Scientific Corp. All other authors declare no conflicts of interest. TABLES Table 1 : Definition of study variables

Fatigue (asthenia) Fatigue ascertained by any validated tool (e.g., FACIT fatigue scale, FSS), or clinical diagnosis of CFS/EM.

Self-report or non-validated measure of fatigue, tiredness/low energy, muscular fatigue/muscular weakness (myasthenia), malaise. Cognitive Impairment Cognitive impairment ascertained by any validated tool for performance-based cognitive function (e.g., MoCA, TICS, SCIP), or clinical diagnosis of cognitive impairment.

Self-report or non-validated measure of cognitive impairment/'brain fog', mental slowness, deficits in attentional, executive, processing, memory, learning, articulation, and/or psychomotor coordination.

Abnormal levels of circulating or intracellular cytokines, CRP, D-dimer, and/or procalcitonin, as per thresholds set by study investigators, or relative to control group or established standard.

Functional impairment (including activity, occupational, and social limitations) 123 as ascertained by any validated tool for quality of life or functional outcomes (e.g., EQ-5D, mRS).

Self-report or non-validated assessment of functional impairment (including activity, occupational, and social limitations), as well as general vitality/quality of life. • Cytokines such as TNF-α were correlated with abnormal clinical features • Significant increases in SAA, TNF-α, and IL-1RA in severe cohort (class 1,2,3 cytokines upregulated in cases) • Higher than normal levels of IL-17A and IL-17D in severe cohort • No difference across all cohorts in IL-1α and IL-1β • Normal levels of IL-6 and IL-10 across all groups • IL-7 was decreased in severe cohort a This article is a pre-print as of June 8, 2021. Proportions are reported as cases/total sample size. Cases refers to previous confirmed COVID-19 cases. Medians reported as median (interquartile range), if the interquartile range was provided, or unless otherwise specified. Means reported as mean ± standard deviation, if the standard deviation was provided. Previously hospitalized/admitted to ICU refers to COVID-19 treatment. Admission and discharge refer to COVID-19 inpatient treatment. Infection refers to infection with SARS-CoV-2. Ages are given in years. %F/%M refers to percentage of sample which is female/percentage of the sample which is male. Table 1 ). Statistically significant subgroup effect sizes, ascertained by p subgroup (χ2 test), are bolded. Acronyms: NOS: Newcastle-Ottawa Scale, N/A: not applicable. 

COVID-19) -World Health Organization

Substantial underestimation of SARS-CoV-2 infection in the United States

Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States

Why the pandemic is 10 times worse than you think

Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network -United States

COVID symptoms, symptom clusters, and predictors for becoming a long-hauler: Looking for clarity in the haze of the pandemic. medRxiv

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Onset and frequency of depression in post-COVID-19 syndrome: A systematic review

Post-acute COVID-19 syndrome

Overview | COVID-19 rapid guideline: managing the long-term effects of COVID-19 | Guidance | NICE

A clinical case definition of post COVID-19 condition by a Delphi consensus

Reflections of a COVID-19 Long Hauler

As Their Numbers Grow, COVID-19 "Long Haulers

Characterizing Long COVID in an international cohort: 7 months of symptoms and their impact. bioRxiv

The lasting misery of coronavirus long-haulers

What does COVID-19 recovery actually look like? -patient-led research collaborative

The hidden cost of chronic fatigue to patients and their families

Economic burden of Alzheimer disease and managed care considerations

Global and regional economic costs of dementia: a systematic review

Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Better systematic review management

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

How to perform a meta-analysis with R: a practical tutorial

Small sample inference for fixed effects from restricted maximum likelihood

The Inverse of the Freeman -Tukey Double Arcsine Transformation

Analysing Data and Undertaking Meta-Analyses

Completing 'Summary of findings' tables and grading the certainty of the evidence. Cochrane Handbook for Systematic Reviews of Interventions

Persistent cellular immunity to SARS-CoV-2 infection

Alterations in T and B cell function persist in convalescent COVID-19 patients

Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial

Post-COVID-19 functional status six-months after hospitalization

Clinical outcomes and quality of life of COVID-19 survivors: A follow-up of 3 months post hospital discharge

Patient-reported outcome measures after COVID-19: a prospective cohort study

Inflammatory profiles and clinical features of COVID-19 survivors three months after discharge in Wuhan

Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort

Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. The Lancet Child & Adolescent Health

Long-term neurological manifestations of COVID-19: prevalence and predictive factors. bioRxiv

Psychological Distress, Persistent Physical Symptoms, and Perceived Recovery After COVID-19 Illness

Prolonged and Late-Onset Symptoms of Coronavirus Disease

Pulmonary function and radiologic features in survivors of critical COVID-19: A 3-month prospective cohort

Long-term post-COVID symptoms and associated risk factors in previously hospitalized patients: A multicenter study

Prevalence of post-COVID-19 cough one year after SARS-CoV-2 infection: A multicenter study

Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort

COVID-19: persistence of symptoms and lung alterations after 3-6 months from hospital discharge. Infection

Long-term clinical, virological and immunological outcomes in patients hospitalized for COVID-19: antibody response predicts long COVID. bioRxiv

Persistent symptoms and association with inflammatory cytokine signatures in recovered Coronavirus disease 2019 patients

Physical, cognitive and mental health impacts of COVID-19 following hospitalisation -a multi-centre prospective cohort study. bioRxiv

Heterogeneity of post-COVID impairment: interim analysis of a prospective study from Czechia

Post-COVID-19 symptom burden: What is long-COVID and how should we manage it? Lung

Clinical and immunoserological status 12 weeks after infection with COVID-19: prospective observational study. bioRxiv

Comprehensive health assessment three months after recovery from acute COVID-19

Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation

IL6 -Clinical: Interleukin 6, Plasma. Accessed

Patient-reported outcome measures after hospitalization during the COVID-19 pandemic, a survey among COVID-19 and non-COVID-19 patients. Research Square

A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications

Post-discharge persistent symptoms and healthrelated quality of life after hospitalization for COVID-19

Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers

Patients with uncomplicated COVID-19 have longterm persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic

Descriptive analysis of long COVID sequela identified in a multidisciplinary clinic serving hospitalised and non-hospitalised patients

Six-month outcome in survivors of COVID-19 associated acute respiratory distress syndrome

Sequelae in adults at 6 months after COVID-19 infection

Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. bioRxiv

Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables

Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study. bioRxiv

Long-COVID syndrome? A study on the persistence of neurological, psychological and physiological symptoms

Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. medRxiv

The association between antibody response to severe acute respiratory syndrome Coronavirus 2 infection and post-COVID-19 syndrome in healthcare workers

Health-related quality of life of COVID-19 patients after discharge: A multicenter follow-up study

Neurological outcome and quality of life 3 months after COVID-19: A prospective observational cohort study

Three-month outcomes in hospitalized COVID-19 patients

Telephone Screening of Cognitive Status (TICS) in severe COVID-19 patients: Utility in the era of social isolation. eNeurologicalSci

Self-reported memory problems eight months after non-hospitalized COVID-19 in a large cohort. bioRxiv

Healthrelated quality of life, functional decline, and long-term mortality in older patients following hospitalisation due to COVID-19

Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients

Longterm outcomes in COVID-19 ICU patients: A prospective cohort study. Research Square

Self-Reported Population Health: An International Perspective Based on EQ-5D

Characterising post-COVID syndrome more than 6 months after acute infection in adults

Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study

Long-term COVID-19 symptoms in a large unselected population. bioRxiv

Limited recovery from post-acute sequelae of SARS-CoV-2 (PASC) at eight months in a prospective cohort

Long-lasting cognitive abnormalities after COVID-19

Follow-up of COVID-19 recovered patients with mild disease. Research Square

High proportion of post-acute sequelae of SARS-CoV-2 infection in individuals 1-6 months after illness and association with disease severity in an outpatient telemedicine population

Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients

Half-year follow-up of patients recovering from severe COVID-19: Analysis of symptoms and their risk factors

Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19

Prevalence and determinants of fatigue after COVID-19 in non-hospitalized subjects: A population-based study

Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study

Post-acute COVID-19 symptoms, a potential link with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A 6-month survey in a Mexican cohort

Long COVID in the Faroe Islands -a longitudinal study among non-hospitalized patients

Post-COVID-19 syndrome in Egyptian healthcare staff: Highlighting the carers sufferings

Health issues and immunological assessment related to wuhan's COVID-19 survivors: A multicenter follow-up study

Persistent symptoms after discharge of COVID-19 patients

COVID-19-related symptoms 6 months after the infection -Update on a prospective cohort study in Germany. bioRxiv

Frequent neurocognitive deficits after recovery from mild COVID-19

Early recovery following new onset anosmia during the COVID-19 pandemic -an observational cohort study

COVID-19 symptoms over time: comparing longhaulers to ME/CFS. Fatigue: Biomedicine, Health & Behavior

Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic

Encephalitis lethargica: 100 years after the epidemic

Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome

COVID-19: from an acute to chronic disease? Potential long-term health consequences

Brain imaging before and after COVID-19 in UK Biobank. bioRxiv

Microvascular injury in the brains of patients with covid-19

18F-FDG brain PET hypometabolism in patients with long COVID

COVID-19 is, in the end, an endothelial disease

A review of persistent post-COVID syndrome (PPCS)

Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments

The impact of inflammation on cognitive function in older adults: implications for healthcare practice and research

Inflamed moods: a review of the interactions between inflammation and mood disorders

Post-infectious encephalitis in adults: diagnosis and management

The anti-inflammatory mechanism of antidepressants -SSRIs, SNRIs

Do workplace-based mindfulness meditation programs improve physiological indices of stress? A systematic review and meta-analysis

Impact of COVID-19 pandemic on mental health in the general population: A systematic review

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records

Expert Consensus on Screening and Assessment of Cognition in Psychiatry

Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force

The THINC-it Tool for Cognitive Assessment and Measurement in Major Depressive Disorder: Sensitivity to Change. Front Psychiatry

The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction: Validation in Patients With Major Depressive Disorder

Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions

What is "functional impairment"? Disentangling disability from clinical significance

Symptoms, pulmonary function and functional capacity four months after COVID-19

Preliminary evidence on long COVID in children

Integrative respiratory follow-up of severe COVID-19 reveals common functional and lung imaging sequelae

Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients

Persistent symptoms in patients recovering from COVID-19 in Denmark

Three-month follow-up study of survivors of Coronavirus disease 2019 after discharge

Neurological and cognitive sequelae of Covid-19: a four month follow-up

Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up

Fourmonth clinical status of a cohort of patients after hospitalization for COVID-19

Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study

Prevalence of fatigue in patients post covid-19

Ninety days post-hospitalization evaluation of residual COVID-19 symptoms through a phone call check list

Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery

Fatigue and cognitive impairment are amongst the most common and debilitating symptoms of post-COVID-19 syndrome

weeks following COVID-19 diagnosis

Narrative synthesis revealed elevations in proinflammatory markers and considerable functional impairment in a subset of individuals